Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Clin Cancer Res. 2016 Nov 30;23(12):3035–3044. doi: 10.1158/1078-0432.CCR-16-2092

Fig 3.

Fig 3

Survival outcomes in HR+ early breast cancer with ROR-intermediate disease. (A) Node-negative disease treated without adjuvant systemic therapy. (B) Node-negative and node-positive disease treated with adjuvant tamoxifen-only. (C) Node-positive disease treated with adjuvant chemotherapy and endocrine therapy in the GEICAM/9906 clinical trial. (D) Node-negative and node-positive disease treated with neoadjuvant chemotherapy and adjuvant endocrine therapy.